tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KAPA Stock Latest News

Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
RatingsKairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
15d ago
KAPA
Kairos Pharma Approves RSUs and Cash Bonuses
PremiumCompany Announcements
Kairos Pharma Approves RSUs and Cash Bonuses
2M ago
8K
KAPA
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
PremiumRatings
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
2M ago
KAPA
Kairos Pharma to Present at ESMO Congress 2025
PremiumCompany Announcements
Kairos Pharma to Present at ESMO Congress 2025
2M ago
8K
KAPA
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
PremiumRatings
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
2M ago
KAPA
Kairos Pharma Reports Positive Phase 2 Trial Results
PremiumCompany AnnouncementsKairos Pharma Reports Positive Phase 2 Trial Results
3M ago
8K
KAPA
Kairos Pharma announces interim efficacy analysis of ENV105
Premium
The Fly
Kairos Pharma announces interim efficacy analysis of ENV105
3M ago
KAPA
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
Premium
Ratings
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
3M ago
KAPA
Kairos Pharma to Host KOL Event on Phase 2 Trial
PremiumCompany Announcements
Kairos Pharma to Host KOL Event on Phase 2 Trial
3M ago
8K
KAPA
Kairos Pharma Presents Phase 1 Data at Conference
PremiumCompany Announcements
Kairos Pharma Presents Phase 1 Data at Conference
3M ago
8K
KAPA
Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating
PremiumRatings
Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating
4M ago
KAPA
Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile
PremiumRatings
Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile
4M ago
KAPA
Kairos Pharma management to meet with Maxim
PremiumThe FlyKairos Pharma management to meet with Maxim
4M ago
KAPA
Why Is Kairos Pharma Stock (KAPA) Up 170% Today?
Premium
Market News
Why Is Kairos Pharma Stock (KAPA) Up 170% Today?
5M ago
KAPA
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
5M ago
ZK
AMD
Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook
PremiumRatings
Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook
5M ago
KAPA
Kairos Pharma Announces Positive Phase 2 Trial Results
PremiumCompany Announcements
Kairos Pharma Announces Positive Phase 2 Trial Results
5M ago
8K
KAPA
Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial
PremiumThe Fly
Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial
5M ago
KAPA
Kairos Pharma Enhances U.S. Investor Relations Strategy
PremiumCompany Announcements
Kairos Pharma Enhances U.S. Investor Relations Strategy
6M ago
8K
KAPA
Promising Developments in Oncology Drive Buy Rating for Kairos Pharma
PremiumRatingsPromising Developments in Oncology Drive Buy Rating for Kairos Pharma
6M ago
KAPA
Kairos Pharma Presents Promising KROS101 Data at ASCO 2025
Premium
Company Announcements
Kairos Pharma Presents Promising KROS101 Data at ASCO 2025
6M ago
8K
KAPA
Kairos Pharma files to sell 16.29M shares of common stock for holders
Premium
The Fly
Kairos Pharma files to sell 16.29M shares of common stock for holders
8M ago
KAPA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >